Emily Walsh1, Young Wha Chah, Samantha M Chin, Paul Lochhead, Vijay Yajnik, Vera Denmark, John J Garber, Hamed Khalili. 1. *Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; †Division of Gastroenterology, Newton Wellesley Hospital, Newton, Massachusetts; and ‡Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: A proportion of patients with initial presentation of ulcerative proctitis (UP) progress to more extensive colitis. We sought to characterize the natural history and identify clinical predictors of extension in UP. METHODS: We performed a retrospective cohort study of participants with a new diagnosis of UP from January 2000 to December 2015. We used Cox proportional hazard modeling to identify predictors of disease extension. RESULTS: We identified 169 new cases of UP with a median age of diagnosis of 40 years (range: 16-91 yr) and a median follow-up of 4.3 years (range: 3.3-15.1 yr). Fifty-three (31%) patients developed extension over the follow-up time. Compared with nonextenders, the need for immunosuppressive or biologic therapy was significantly higher among extenders (34% versus 2.6%, P < 0.001). In multivariable analyses, compared with UP cases with body mass index <25, the adjusted hazard ratios of extension were 1.75 (95% confidence interval [CI], 0.95-3.23) and 2.77 (95% CI, 1.07-7.14) among overweight and obese patients, respectively (Ptrend = 0.03). Similarly, patients with a history of appendectomy or endoscopic finding of moderate to severe disease had a higher risk of extension (adjusted hazard ratio = 2.74, 95% CI, 1.07-7.01 and 1.96, 95% CI, 1.05-3.67, respectively). CONCLUSIONS: In a retrospective cohort study, we show that appendectomy, body mass index, and endoscopic activity at the time of diagnosis of proctitis are associated with an increased risk of extension. In addition, our data suggest that extenders are more likely to require immunosuppressive or biologic therapy.
BACKGROUND: A proportion of patients with initial presentation of ulcerative proctitis (UP) progress to more extensive colitis. We sought to characterize the natural history and identify clinical predictors of extension in UP. METHODS: We performed a retrospective cohort study of participants with a new diagnosis of UP from January 2000 to December 2015. We used Cox proportional hazard modeling to identify predictors of disease extension. RESULTS: We identified 169 new cases of UP with a median age of diagnosis of 40 years (range: 16-91 yr) and a median follow-up of 4.3 years (range: 3.3-15.1 yr). Fifty-three (31%) patients developed extension over the follow-up time. Compared with nonextenders, the need for immunosuppressive or biologic therapy was significantly higher among extenders (34% versus 2.6%, P < 0.001). In multivariable analyses, compared with UP cases with body mass index <25, the adjusted hazard ratios of extension were 1.75 (95% confidence interval [CI], 0.95-3.23) and 2.77 (95% CI, 1.07-7.14) among overweight and obesepatients, respectively (Ptrend = 0.03). Similarly, patients with a history of appendectomy or endoscopic finding of moderate to severe disease had a higher risk of extension (adjusted hazard ratio = 2.74, 95% CI, 1.07-7.01 and 1.96, 95% CI, 1.05-3.67, respectively). CONCLUSIONS: In a retrospective cohort study, we show that appendectomy, body mass index, and endoscopic activity at the time of diagnosis of proctitis are associated with an increased risk of extension. In addition, our data suggest that extenders are more likely to require immunosuppressive or biologic therapy.
Authors: M Naganuma; B Iizuka; A Torii; T Ogihara; Y Kawamura; M Ichinose; Y Kojima; T Hibi Journal: Am J Gastroenterol Date: 2001-04 Impact factor: 10.864
Authors: H Anzai; K Hata; J Kishikawa; H Ishii; T Nishikawa; T Tanaka; J Tanaka; T Kiyomatsu; K Kawai; H Nozawa; S Kazama; H Yamaguchi; S Ishihara; E Sunami; J Kitayama; T Watanabe Journal: Colorectal Dis Date: 2016-03 Impact factor: 3.788
Authors: H Anzai; K Hata; J Kishikawa; H Ishii; K Yasuda; K Otani; T Nishikawa; T Tanaka; T Kiyomatsu; K Kawai; H Nozawa; S Kazama; H Yamaguchi; S Ishihara; E Sunami; T Watanabe Journal: Colorectal Dis Date: 2016-08 Impact factor: 3.788
Authors: A Hochart; C Gower-Rousseau; H Sarter; M Fumery; D Ley; C Spyckerelle; L Peyrin-Biroulet; J-E Laberenne; F Vasseur; G Savoye; D Turck Journal: Gut Date: 2016-08-03 Impact factor: 23.059
Authors: Peter J Turnbaugh; Ruth E Ley; Michael A Mahowald; Vincent Magrini; Elaine R Mardis; Jeffrey I Gordon Journal: Nature Date: 2006-12-21 Impact factor: 49.962
Authors: S Sahami; I A Kooij; S L Meijer; G R Van den Brink; C J Buskens; A A Te Velde Journal: Am J Gastroenterol Date: 2015-09-29 Impact factor: 10.864
Authors: Sunil Samuel; Steven B Ingle; Shamina Dhillon; Siddhant Yadav; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; William J Sandborn; Edward V Loftus Journal: Inflamm Bowel Dis Date: 2013-08 Impact factor: 5.325
Authors: Ruth E Ley; Fredrik Bäckhed; Peter Turnbaugh; Catherine A Lozupone; Robin D Knight; Jeffrey I Gordon Journal: Proc Natl Acad Sci U S A Date: 2005-07-20 Impact factor: 11.205
Authors: Sandro da Costa Ferreira; Lilian Rose Otoboni Aprile; Rogério Serafim Parra; Marley Ribeiro Feitosa; Gleici de Castro da Silva Perdoná; Omar Féres; José Joaquim Ribeiro da Rocha; Luiz Ernesto de Almeida Troncon Journal: Turk J Gastroenterol Date: 2022-04 Impact factor: 1.555